Monopar Therapeutics Inc. (MNPR) - 10-K Summary
Business Context and Reporting Period
Company: Monopar Therapeutics Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Monopar is a clinical-stage biopharmaceutical company focused on two primary areas: (1) ALXN1840, a late-stage oral treatment for Wilson disease (a rare genetic disorder), and (2) a radiopharmaceutical pipeline targeting uPAR-expressing advanced cancers (MNPR-101-Zr for imaging, MNPR-101-Lu for therapy, and MNPR-101-Ac in preclinical development). The company has no approved products and has not generated revenue from product sales.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(13.72) million | $(15.59) million |
| Operating Expenses | $16.70 million | $16.16 million |
| Research & Development (R&D) | $9.90 million | $13.01 million |
| General & Administrative (G&A) | $6.80 million | $3.16 million |
| Cash, Cash Equivalents & Investments | $140.46 million | $60.29 million |
| Accumulated Deficit | $(89.51) million | $(75.79) million |
| Net Cash Used in Operating Activities | $(12.20) million | $(6.40) million |
| Net Cash Provided by Financing Activities | $91.57 million | $59.29 million |
Note: The company reported no debt as of December 31, 2025. Liquidity is supported by cash and investments totaling $140.46 million.
Material Changes vs. Prior Period
- Capital Raise: In September 2025, the company completed a public offering raising approximately $126.9 million (gross) from the sale of common stock and pre-funded warrants. Concurrently, it repurchased 550,229 shares from a significant shareholder (Tactic Pharma) for $35 million, resulting in net proceeds of approximately $91.9 million.
- Asset Acquisition: In October 2024, Monopar acquired an exclusive worldwide license for ALXN1840 from Alexion Pharmaceuticals (AstraZeneca). The upfront consideration included $4.0 million in cash (paid in 2024 and 2025) and the issuance of common stock. This asset was previously terminated by Alexion despite meeting Phase 3 primary endpoints, due to concerns over copper balance data.
- Expense Fluctuations: R&D expenses decreased by $3.1 million year-over-year, primarily due to the absence of one-time in-licensing costs incurred in 2024. G&A expenses increased by $3.6 million, driven by higher personnel costs, stock-based compensation, and Board compensation.
- Interest Income: Interest income surged to $2.99 million in 2025 from $0.40 million in 2024, reflecting higher cash balances and investment yields following the capital raises.
Guidance, Outlook, and Risks
Outlook and Guidance:
- ALXN1840: Management expects to submit a New Drug Application (NDA) to the FDA in mid-2026. The company is currently assembling the regulatory package and engaging in dialogue with the FDA regarding specific questions.
- Radiopharmaceuticals: Phase 1 trials for MNPR-101-Zr (imaging) and MNPR-101-Lu (therapy) are active. An Expanded Access Program (EAP) for these agents was authorized by the FDA in June 2025.
- Liquidity: Management estimates current funds ($140.4 million as of Dec 31, 2025) are sufficient to fund operations through at least December 31, 2027.
Key Risks and Contingencies:
- Regulatory Uncertainty: The FDA has not yet accepted the NDA for ALXN1840. Approval is not guaranteed, and the FDA may require additional studies. The program was previously terminated by Alexion due to mechanistic trial data, creating a heightened regulatory hurdle.
- Capital Requirements: The company expects to continue incurring significant losses. Future funding will be required for commercialization if approved, and additional financing may be needed before then.
- Manufacturing and Supply Chain: Reliance on third-party manufacturers for radiopharmaceuticals poses risks related to shelf-life, logistics, and supply of radioisotopes (e.g., Actinium-225).
- Intellectual Property: Some patents for the MNPR-101 antibody are nearing expiration (2027-2029), though derivative radiopharmaceutical patents extend to 2041.
Investor Verification Checklist
- NDA Submission Timeline: Verify the specific date and status of the ALXN1840 NDA submission expected in mid-2026 and any FDA feedback received.
- Cash Burn Rate: Monitor quarterly cash usage to confirm the runway extends through 2027 as projected, given the high costs of clinical trials and regulatory preparation.
- Regulatory Dialogue: Review any subsequent filings (8-Ks) detailing the nature of the FDA's questions regarding ALXN1840 and the company's response strategy.
- Radiopharmaceutical Trial Data: Track enrollment and preliminary safety/efficacy data from the Phase 1 MNPR-101-Zr and MNPR-101-Lu trials.
- License Obligations: Confirm the status of milestone payments to Alexion (up to $94 million) and XOMA (up to $14.9 million) and the potential impact on future cash flows upon regulatory approval.